US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares MSCI Pacific ex Japan ETF

58.08

+0.66001.15%

Post-market: 58.080.00000.00%16:10 EDT

Volume:139.69K

Turnover:8.11M

Market Cap:2.33B

PE:6.84

High:58.15

Open:57.96

Low:57.84

Close:57.42

52wk High:58.15

52wk Low:48.93

Shares:40.20M

Float Shares:40.20M

Volume Ratio:0.59

T/O Rate:0.35%

Dividend:1.90

Dividend Rate:3.28%

EPS(TTM):8.50

EPS(LYR):8.50

ROE:25.94%

ROA:1.81%

PB:1.09

PE(LYR):6.84

Loading ...

Overview Company News Filings

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile

Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting

Asia-Pacific Stocks Extend Gains Toward Best February on Record, Kospi Surges 18% Monthly

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/EPP/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","market":"US","secType":"STK","nameCN":"iShares MSCI Pacific ex Japan ETF","latestPrice":58.08,"timestamp":1787342400000,"preClose":57.42,"halted":0,"volume":139685,"hourTrading":{"tag":"盘后","latestPrice":58.08,"preClose":58.08,"latestTime":"16:10 EDT","volume":10,"amount":580.33,"timestamp":1787343004676,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01149425287356316,"floatShares":40200000,"shares":40200000,"eps":8.495214,"marketStatus":"Market Closed","change":0.66,"latestTime":"08-21 16:00:00 EDT","open":57.96,"high":58.15,"low":57.84,"amount":8110708,"amplitude":0.005399,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.495214,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":57.42,"sharesOutstanding":38400000,"nav":58.20238,"aum":2339735676,"dividendRate":0.032789,"bidAskSpread":0.000345,"preHourTrading":{"tag":"盘前","latestPrice":57.42,"preClose":57.42,"latestTime":"04:00 EDT","volume":4,"amount":229.68,"timestamp":1787299205923,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":58.08,"preClose":58.08,"latestTime":"16:10 EDT","volume":10,"amount":580.33,"timestamp":1787343004676,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5917557075063786,"impliedVol":0.0325,"impliedVolPercentile":0.0398},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","floatShares":40200000,"roa":"1.81%","roe":"25.94%","lyrEps":8.495214,"volumeRatio":0.5917557075063786,"shares":40200000,"dividePrice":1.904369,"high":58.15,"amplitude":0.005399,"preClose":57.42,"low":57.84,"week52Low":48.93,"pbRate":"1.09","psRate":"34.08","week52High":58.15,"institutionHeld":0,"latestPrice":58.08,"eps":8.495214,"divideRate":0.032789,"volume":139685,"delay":0,"ttmEps":8.495214,"open":57.96,"prevYearClose":50.47,"prevWeekClose":57.05,"prevMonthClose":56.5,"prevQuarterClose":53.26,"fiveDayClose":57.05,"twentyDayClose":55.41,"sixtyDayClose":55.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPP\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"EPP","amount":0.824127,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"EPP","amount":1.045605,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"EPP","amount":0.858764,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"EPP","amount":0.96746,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"EPP","amount":0.70131,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPP\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-28","value":0.90607,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.756156,"currency":"USD"},{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-25","value":0.867553,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":"2018-12-19","paymentDate":"2018-12-24","value":1.166804,"currency":"USD"},{"executeDate":"2019-06-17","recordDate":"2019-06-18","paymentDate":"2019-06-21","value":0.842441,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPP\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642446058","title":"Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642446058?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:30","pubTimestamp":1781008200,"startTime":"0","endTime":"0","summary":"Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308825/0/en/Disc-Medicine-Provides-Update-from-FDA-Type-A-Meeting-for-Bitopertin-in-Erythropoietic-Protoporphyria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU0757428866.USD","LU1815336091.USD","LU0029874061.USD","LU0128526141.USD","BK4121","BK4530","BK4139","IE00BFMHRM44.USD","XLP","LU0053671581.USD","BK4582","BK4585","IRON","EPP","CRL","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951219","title":"Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951219","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951219?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317000,"startTime":"0","endTime":"0","summary":"The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decisionBitopertin, an oral glycine t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304352/0/en/Disc-Medicine-Launches-Expanded-Access-Program-for-Bitopertin-for-EPP-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","IE00BFMHRM44.USD","BK4582","LU0390134368.USD","BK4121","BK4588","LU0053671581.USD","IRON","LU0757428866.USD","LU1815336091.USD","BK4585","EPP","BK4139","XLP","LU0128526141.USD","BK4530","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948138","title":"Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948138?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment of the Phase 3 APOLLO study of bitopertin in. erythropoietic protoporphyria ; topline data expected in Q4 2026. -- Updated data from Phase 2 study of DISC-0974 in patients with anemia of. myelofibrosis  to be shared at the American Society of Clinical. -- Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera . and Phase 1b study of DISC-3405 in sickle cell disease , with data. cash, cash equivalents, and marketable securities, providing runway into. adults and adolescents with EPP, with topline data expected Q4 2026;anemia of myelofibrosis  to be shared in an oral presentation at ASCO. -- Progressing Phase 2 study in patients with inflammatory bowel disease","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4582","LU0053671581.USD","IBD","EPP","SCD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629926808","title":"CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629926808","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629926808?lang=en_us&edition=fundamental","pubTime":"2026-04-24 13:47","pubTimestamp":1777009620,"startTime":"0","endTime":"0","summary":"“Totality of evidence” approach to evaluate SCENESSEEXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/24/3280522/0/en/CLINUVEL-receives-final-EMA-scientific-advice-for-pivotal-Phase-III-vitiligo-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFB","BK4081","BK4582","EPP","CHMP","BK4211","BK4087","EMA","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627840160","title":"CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627840160","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627840160?lang=en_us&edition=fundamental","pubTime":"2026-04-15 14:18","pubTimestamp":1776233880,"startTime":"0","endTime":"0","summary":"AAD 2026 reinforces CLINUVEL’s expertise in dermatology. Step inside CLINUVEL’s Pavilion of Photomedicine and experience the energy of AAD 2026 through an exclusive video featuring behind-the-scenes of construction, expert insights from the CLINUVEL team and immersive visuals of guests engaging within the Pavilion.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274140/0/en/CLINUVEL-advancing-peptides-for-photomedicine-and-vitiligo-care-at-AAD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","EPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624526648","title":"Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2624526648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624526648?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:29","pubTimestamp":1775093349,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel used the 2026 American Academy of Dermatology Annual Meeting in Denver ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-leverages-aad-2026-to-advance-vitiligo-epp-strategy-and-u-s-profile?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-leverages-aad-2026-to-advance-vitiligo-epp-strategy-and-u-s-profile?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4582","EPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989400","title":"Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989400","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989400?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:03","pubTimestamp":1774562622,"startTime":"0","endTime":"0","summary":"An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals is showcasing its melanocortin-based program...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-showcases-ai-vitiligo-tool-and-epp-therapy-at-major-u-s-dermatology-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-showcases-ai-vitiligo-tool-and-epp-therapy-at-major-u-s-dermatology-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIPO","AGIX","BK4582","EPP","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147203609","title":"Asia-Pacific Stocks Extend Gains Toward Best February on Record, Kospi Surges 18% Monthly","url":"https://stock-news.laohu8.com/highlight/detail?id=1147203609","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147203609?lang=en_us&edition=fundamental","pubTime":"2026-02-27 11:59","pubTimestamp":1772164769,"startTime":"0","endTime":"0","summary":"Asian equities are advancing toward their strongest February performance in history as of February 27, driven by significant investor purchases of companies providing artificial intelligence (AI)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU1066053197.SGD","LU0708994859.HKD","NVDS.UK","LU0788109477.HKD","LU1267930490.SGD","LU2125909916.SGD","LU0889565833.HKD","LU0354030511.USD","BK4550","LU2294711713.HKD","LU1935042991.SGD","LU0056508442.USD","LU0345770993.USD","LU0210536198.USD","LU0106261372.USD","LU2458330243.SGD","IE0004086264.USD","LU2471134796.USD","LU2360032135.SGD","LU2458330169.SGD","LU1633808545.USD","SG9999014914.USD","BK4529","IE00BFSS8Q28.SGD","LU1983260115.SGD","LU0072462426.USD","LU2023251221.USD","LU0965509010.AUD","LU1280957306.USD","LU1935043023.USD","LU1814569148.SGD","IE00B19Z9505.USD","LU1242518931.SGD","BK4554","LU1935043536.SGD","NVDW","LU1642822529.SGD","LU2602419157.SGD","SG9999015978.USD","LU0238689110.USD","LU0943347566.SGD","LU0345768740.USD","LU1720051108.HKD","LU2491050154.USD","LU2361045086.USD","LU2471134952.CNY","LU2264538146.SGD","LU0070217475.USD","LU1116320901.HKD","SG9999015952.SGD","LU0187121727.USD","LU2552382215.SGD","IE00BQXX3D17.EUR","LU0256863902.USD","LU2860962120.EUR","LU0289961442.SGD","LU0175139822.USD","LU0466842654.USD","LU1951198990.SGD","LU0347712357.USD","2NVD.UK","LU0057025933.USD","LU2065171311.SGD","IE0034235303.USD","LU1316542783.SGD","LU1721428933.USD","LU2168564495.EUR","LU0820561909.HKD","BK4581","LU2125909593.SGD","SGXZ99366536.SGD","LU2272731865.HKD","LU2420271590.USD","LU1917777945.USD","BK4503","LU0823421416.USD","LU2357305700.SGD","EWY","LU2506951792.HKD","LU2249611893.SGD","LU1992135399.USD","LU2125154778.USD","SGXZ31699556.SGD","LU1429558221.USD","LU0557290698.USD","NVD2.UK","LU1066051811.HKD","LU1037948897.HKD","LU2463028550.USD","BK4543","LU1868836757.USD","LU1496350171.SGD","SG9999014575.USD","LU0109392836.USD","LU0094547139.USD","IE0005OL40V9.USD","LU2746668974.SGD","LU0985320562.USD","IE000ITXATA3.USD","LU0689472784.USD","LU2272731782.SGD","LU1914381329.SGD","LU2491050071.SGD","IE00BK4W5M84.HKD","LU0316494557.USD","LU1852331112.SGD","LU0642271901.SGD","LU2242649171.HKD","IE00BKPKM429.USD","BK4598","LU2543165471.USD","SNVD.UK","LU0786609619.USD","HK0000914686.HKD","IE00BZ199S13.USD","LU2750360997.AUD","IE00B19Z8W00.USD","LU2487616109.SGD","LU2168564222.USD","LU1435385759.SGD","LU1496350502.SGD","LU0787776722.HKD","LU1267930573.SGD","HK0000320223.HKD","LU2054465674.USD","LU0170899867.USD","BK4614","LU2756315318.SGD","IE00B1BXHZ80.USD","LU0210533765.USD","IE000YTNTUN2.SGD","IE0034235188.USD","LU1923623000.USD","LU0957808578.USD","IE00BKDWB100.SGD","LU1244550494.USD","LU2111349929.HKD","LU1571399168.USD","LU2430703251.USD","LU0029864427.USD","LU0096362180.USD","NVDX","LU1934455194.USD","LU0823421333.USD","LU0708995401.HKD","GB00BDT5M118.USD","LU1923622291.USD","LU0310800379.SGD","LU2237438978.USD","LU0266013472.USD","NVD","HK0000320264.USD","LU0109391861.USD","LU2290526834.HKD","LU2237957811.SGD","LU1629891620.HKD","LU2125154935.USD","LU0640476718.USD","LU0345768153.USD","LU0158827781.USD","LU0345770308.USD","LU1084165304.USD","LU2403377893.USD","IE00BJTD4V19.USD","IE00BJJMRX11.SGD","LU2413666699.HKD","LU2236285917.USD","DIPS","LU2272731600.USD","SG9999014898.SGD","LU0107464264.USD","LU2452424414.USD","LU0128525929.USD","LU2360106780.USD","LU2065171402.SGD","LU0868494617.USD","BK4587","LU2211815571.USD","LU1989764748.USD","LU0323591593.USD","LU2552382132.HKD","LU2322448957.HKD","LU2592432038.USD","LU1868837136.USD","LU1974910355.USD","LU1037948541.HKD","LU2361044865.SGD","LU2023250330.USD","LU2265009873.SGD","LU0724617625.USD","LU2106854487.HKD","LU2471134879.HKD","LU2756315664.SGD","BK4579","IE00BZ1G4Q59.USD","LU0719512351.SGD","ANV","LU0124676726.USD","LU0158827948.USD","LU2552382058.USD","SGXZ51526630.SGD","LU2065170008.USD","NVDG","SG9999017495.SGD","LU1803068979.SGD","LU1923622614.USD","IE00BJJMRY28.SGD","LU1244550221.USD","LU0006306889.USD","LU0820561818.USD","IE00B3SWFQ91.USD","LU0494093205.USD","LU0157215616.USD","LU1992135472.HKD","LU0061475181.USD","LU0882574139.USD","HK0000306701.USD","LU0476273544.USD","LU0011850046.USD","LU2247934214.USD","IE0004445015.USD","LU2417539215.USD","LU2089284900.SGD","LU1934455863.HKD","SG9999014542.SGD","LU1232071149.USD","BK4567","BK4534","LU2271345857.HKD","LU2092937148.SGD","LU2097344357.USD","LU2092627202.USD","IE0001KFT4U8.USD","LU0289739343.SGD","LU1323610961.USD","LU0823434740.USD","LU0251132253.USD","LU1951200564.SGD","SG9999015358.SGD","LU1989772923.USD","LU2244417387.USD","LU0053666078.USD","LU0868494708.USD","LU2250418816.HKD","IE00BN29S564.USD","IE00BD6J9T35.USD","LU2089283258.USD","LU2381873111.SGD","IE00B3M56506.USD","LU2168564149.EUR","IE00B4YYXB79.USD","LU0127658192.USD","BK4608","IE0004091025.USD","LU0942090050.USD","LU0069063385.USD","LU1674673691.USD","LU2242650005.HKD","LU1868836914.USD","LU1116320737.USD","LU1551013425.SGD","LU0823414551.USD","LU1674673428.USD","SG9999015986.USD","IE00BHPRN162.USD","SG9999014906.USD","IE00BYXW3230.USD","NVDQ","IE00BMPRXN33.USD","LU0965509283.SGD","LU0353189763.USD","EPP","LU0080751232.USD","BK4588","LU1839511570.USD","LU1366333091.USD","LU0048584097.USD","LU2931357623.SGD","LU2746668461.USD","LU2023250504.SGD","LU0965508806.USD","IE00B19Z8X17.USD","LU0354030438.USD","IE0009G5SDU7.USD","LU0965509101.SGD","LU0225283273.USD","LU1242518857.USD","LU2087625088.SGD","LU0348723411.USD","HK0000914660.USD","LU1261432733.SGD","LU1244550577.SGD","LU2108987350.USD","LU0234570918.USD","LU0274383776.USD","IE00BJLML261.HKD","IE000KEQY171.SGD","3NVD.UK","LU1551013342.USD","SG9999018865.SGD","IE0009356076.USD","SG9999018857.SGD","LU0353189680.USD","LU2357125470.USD","LU0210528500.USD","NVII","LU1720051017.SGD","LU2473716301.USD","LU1989772840.SGD","LU1066051225.USD","LU2430703178.SGD","LU1861215975.USD","LU2237957902.USD","NVDD","LU0154236417.USD","LU2896262040.SGD","LU1267930730.SGD","LU1691799644.USD","IE0034235295.USD","LU1366192091.USD","IE00B775SV38.USD","IE00BDRTCR15.USD","LU0096364046.USD","SGXZ81514606.USD","NVIW.SI","LU1988902786.USD","SG9999015945.SGD","SG9999014559.SGD","LU0672654240.SGD","LU1127390331.HKD","IE0004445239.USD","LU0345769631.USD","LU0211328371.USD","LU0265550946.USD","SG9999004303.SGD","LU0203201768.USD","IE00BMPRXQ63.HKD","SG9999002224.SGD","LU2213496289.HKD","LU0276348264.USD","SG9999014567.USD","LU2505996509.AUD","LU1069344957.HKD","LU2413666426.HKD","IE00BQXX3C00.GBP","LU2462157665.USD","SG9999015341.SGD","LU0320765059.SGD","IE00BFSS7M15.SGD","LU0198837287.USD","LU2361044949.HKD","LU1815336760.USD","LU2430703095.HKD","LU0823414478.USD","IE00BK4W5L77.USD","LU0081259029.USD","BK4612","LU0097036916.USD","LU0211327993.USD","LU1712237335.SGD","LU1868837300.USD","LU0310799852.SGD","LU2491049909.HKD","IE00BQXX3F31.USD","LU1791710400.SGD","BK1147","LU0823434583.USD","LU1064131342.USD","LU1035775433.USD","LU2168563687.JPY","LU2461242641.AUD","LU0342679015.USD","LU0082616367.USD","LU2125909759.SGD","IE00B7KXQ091.USD","LU1145028129.USD","LU1935042215.USD","LU0234572021.USD","LU2168564065.EUR","LU2286300806.USD","LU1804176565.USD","LU1066051498.USD","SGXZ23171101.USD","LU0256863811.USD","LU1815333072.USD","IE00B5949003.HKD","LU1548497426.USD","LU0957791311.USD","BK4551","LU0417517546.SGD","LU0689626769.HKD","IE00B1XK9C88.USD","NVDS","LU1821325948.USD","LU0289960550.SGD","LU0390134368.USD","LU2471134523.USD","LU1153585028.USD","LU0345769128.USD","LU0979878070.USD","LU2191332357.HKD","LU1989764664.SGD","IE000W1ABFV2.USD","LU2433249047.HKD","SG9999001424.SGD","BK4592","LU2456880835.USD","NVDL","SG9999000418.SGD","BK4549","SG9999014880.SGD","LU0472753341.HKD","BK4527","LU0265550359.USD","LU0061474960.USD","LU1935042488.USD","LU0444973449.USD","LU1778281490.HKD","LU0528227936.USD","IE00BKVL7J92.USD","IE0003U64NQ7.SGD","LU1791710582.SGD","LU2077746001.SGD","NVDU","LU2505996681.GBP","LU2326559502.SGD","LU0683600562.USD","IE00BMPRXR70.SGD","LU0964807845.USD","LU2028103732.USD","LU0215105999.USD","LU0061474705.USD","LU1861220033.SGD","LU1718418525.SGD","LU2087621335.USD","LU2097344431.USD","BK4585","LU0203202063.USD","LU0444971666.USD","LU2063271972.USD","IE00BWXC8680.SGD","LU1623119135.USD","LU2360107168.USD","LU0861579265.USD","IE00B4JS1V06.HKD","NVD3.UK","BK4532","LU0077335932.USD","LU2750360641.GBP","LU2065169927.USD","SG9999002232.USD","LU2125909247.SGD","NVDA","LU2322448791.USD","HK0000306685.HKD","LU0308772762.SGD","BK4548","LU1119994496.HKD","IE00B775H168.HKD","BK4605","BK4533","NVDY","LU1861127337.USD","IE00B3S45H60.SGD","LU1868836591.USD","LU0267386448.USD","LU0511384066.AUD","LU0079474960.USD","BK4141","IE00BJTD4N35.SGD","LU1934455277.USD","LU0820562030.AUD","IE00BDCRKT87.USD","LU2089985449.USD","NVDB","LU2083900584.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614042239","title":"Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614042239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614042239?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:30","pubTimestamp":1772112600,"startTime":"0","endTime":"0","summary":"-- Pursuing a traditional approval path for bitopertin in erythropoietic. protoporphyria ; Phase 3 APOLLO study is expected to complete. enrollment in March 2026 with topline data expected in Q4 2026. -- Initial data from Phase 2 study of DISC-0974 in patients with anemia of. myelofibrosis  presented at the American Society of Hematology . conference demonstrating meaningful overall anemia responses across all. patient subgroups, regardless of baseline transfusion status or. -- Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera . and initiated a Phase 1b study of DISC-3405 in sickle cell disease . in Q4 2025, with data from both studies expected in 2H 2026. cash, cash equivalents, and marketable securities, providing runway into. Administration  in February 2026 related to sufficiency of evidence. adolescents with EPP, with topline data expected Q4 2026. anemia of myelofibrosis  presented at ASH Annual Meeting i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","IBD","LU1815336091.USD","LU0390134368.USD","BK4121","LU0053671581.USD","SCD","BK4530","BK4585","LU0757428866.USD","EPP","LU0128526141.USD","BK4139","ASH","BK4582","BK4588","IRON","LU0029874061.USD","LU2463526074.USD","IE00BFMHRM44.USD","BK4109"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":89,"code":"91000000","status":"200"}]}}